Business Wire

NY-HANSHOW

16.1.2023 15:01:38 CET | Business Wire | Press release

Share
Hanshow Unveils New Generation Protocol and Four-Color ESL at NRF 2023

Hanshow participated in the 2023 National Retail Federation (NRF), the largest retail event in the world. At this year’s NRF Exhibition Booth, Hanshow unveiled a new generation protocol high-density low-power cellular network (HiLPC) and four-color Electronic Shelf Label (ESL). Hanshow has strengthened the operability of both its hardware and software and now provides more advanced solutions and services for the digital upgrading of retail industry customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005732/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hanshow's new generation protocol high-density low-power cellular network (HiLPC) (Graphic: Business Wire)

Rapid upgrading that is more than just “fast”

Hanshow already provided the world’s leading series of ESL products, and this advanced performance has been further improved through Hanshow’s new generation HiLPC. With HiLPC innovative system architecture, the communication speed of the ESL is greatly improved, and the update speed can reach over 60,000 pieces/hour/ESL controller, making it quicker and easier to install and bind. The super-high system throughput of the HiLPC enables updating tens of millions of devices within a few minutes, which brings clients a totally novel experience of real-time ESL services and enhances clients’ capability of managing globally distributed stores.

With this upgraded protocol, Hanshow ESL Solution enables batch, timed, and synchronized task updates in the same store with errors controlled at the millisecond level, and it can also synchronize dynamic price changes, realize precise timing synchronization while online and even offline, and track the position of products, greatly improving the operational efficiency of stores.

The new generation HiLPC makes it possible to nomadically update ESLs, which opens opportunities for new industrial applications. It also supports flashing light prompts for any number of goods being selected to help employees quickly find the location of goods for sorting. It supports dynamic network resource allocation used in conjunction with Wi-Fi, solving the network incompatibility challenges. In addition, the new generation protocol combined with ESL controllers and financial-grade security chips provides the most reliable data protection available.

Breaking through with smarter and better performance

Hanshow also unveiled the four-color ESL product series that supports black, white, red, and yellow color displays in any combination, expanding the digital display possibilities for retailers. This product’s screen updating and flashing speeds are significantly optimized compared with previous models, especially in conjunction with the new generation HiLPC.

In addition to the breakthrough in vivid displays, Hanshow has focused on increasing its precision applications for specific industry demands. Hanshow’s thermal detector and DIY ESL solutions are designed to help retailers solve special applications for temperature monitoring and automatic temperature change alerts, as well as the product use adaptation problems of home improvement retail and other business forms.

For years, Hanshow has pursued continuous innovation based on customer needs and remained committed to enabling customers to achieve upgrading for better operational efficiency. The new generation HiLPC and four-color ESL directly achieve this by drastically reducing the energy supply and paper materials needed to operate a physical store. In the future, Hanshow will continue developing innovative digital technology, fully assist customers in digital upgrading, and create a green, leading, and sustainable digital new experience in the industry.

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005732/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye